RETRACTED ARTICLE: Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis

Abstract

BackgroundLong noncoding RNAs (LncRNAs) have been reported to be abnormally expressed in human ovarian cancer and associated with the proliferation and metastasis of cancer cells. The objective of this study was to investigate the role and the underlying mechanisms of LncRNA MAP3K20 antisense RNA 1 (MLK7-AS1) in ovarian cancer.MethodsThe expression level of MLK7-AS1 was investigated in human ovarian cancer tissues and cell lines. The effects of MLK7-AS1 knockdown on ovarian cancer cell proliferation, migration, invasion and apoptosis were evaluated in vitro using MTT, colony formation assays, wound healing assays, transwell assays and flow cytometry. Furthermore, the in vivo effects were determined using the immunodeficient NSG female mice. Luciferase reporter assays were employed to identify interactions among MLK7-AS1 and its target genes.ResultsIn the current study, MLK7-AS1 was specifically upregulated in ovarian cancer tissues and cell lines. Knockdown of MLK7-AS1 inhibited the ability of cell migration, invasion, proliferation, colony formation and wound healing, whereas promoted cell apoptosis in vitro. By using online tools and mechanistic analysis, we demonstrated that MLK7-AS1 could directly bind to miR-375 and downregulate its expression. Besides, MLK7-AS1 reversed the inhibitory effect of miR-375 on the growth of ovarian cancer cells, which might be involved in the upregulation of Yes-associated protein 1 (YAP1) expression. Moreover, knockdown MLK7-AS1 expression inhibited primary tumor growth in ovary and metastatic tumors in multiple peritoneal organs including liver and spleen in vivo, which were partly abolished by miR-375 inhibition. Mechanically, we found that MLK7-AS1 modulated the epithelial-mesenchymal transition (EMT) process by interacting with miR-375/YAP1 both in vivo and vitro, which promoted the expression of Slug.ConclusionsTaken together, our study showed for the first time that MLK7-AS1 interacted with miR-375 to promote proliferation, metastasis, and EMT process in ovarian cancer cells through upregulating YAP1.

An integrated analysis reveals the oncogenic function of lncRNA LINC00511 in human ovarian cancer

“…Recently, a great number of lncRNAs in human ovarian cancers have been reported. For instance, Yan et al reported that lncRNA MLK7‐AS1 was up‐regulated in ovarian cancer tissues and cell lines, and promoted cell proliferation, migration and invasion through binding to miR‐375 and thereby reversing its inhibitory effect on regulating the Yes‐associated protein 1 (YAP1) expression in ovarian cancer . Although some ovarian cancer related lncRNAs have been identified, the functional roles of many other lncRNAs in ovarian cancer are still unknown.…”

LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer

“…For example, previous study showed that lncRNA DQ786243 was upregulated in OSC cells, and knockdown of DQ786243 inhibited cell progression of via regulating miR-506 [8]. Besides, lncRNA MLK7-AS1 promoted migration of OSC cells via miR-375/YAP1 axis [9]. Moreover, Lin28A…”

Identification of long noncoding RNA RP11-89K21.1 and RP11-357H14.17 as prognostic signature of endometrial carcinoma via integrated bioinformatics analysis

“…LncRNAs, as important regulators of transcription and translation, have been found not only involved in physiological and pathological processes, including chromatin remodeling, transcription, post-transcriptional translation, cell proliferation, differentiation and metabolic reprogramming [4][5], but also playing a pivotal role in the occurrence and development of malignant tumors [6]. Abnormal expression of lncRNAs can affect the development and progression of many kinds of malignant tumors, such as prostate cancer [7], ovarian cancer [8], breast cancer [9] and gastric cancer [10]. In recent years, a variety of lncRNAs have been identi ed to be essential for the initiation, progression and malignant behaviors of endometrial carcinoma [11].…”